United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Symic Bio initiates SB-030 Phase 1/2a study in peripheral artery disease Symic Bio, a biopharmaceutical company based in California specializing in matrix biology, is set to commence a phase… bypharmanewsdailyFebruary 25, 2017